According to GlobalData’s Pharmaceutical Intelligence Center, the number of 10-year diagnosed prevalent cases of Wilson’s disease in India is expected to increase at an annual growth rate (AGR) of 0.36 per cent from 53,988 in 2023 to 55,150 in 2030
In November 2023, the Indian Union Health Ministry authorised the sale of four generic medications for the treatment of rare diseases. This approval is a significant milestone in the fight against rare diseases in India. These approved indigenous products, along with other products yet to be approved, will aid patients suffering from rare diseases. However, a major obstacle to effectively combating rare diseases in India is the lack of awareness and inadequate diagnosis in the country, says GlobalData.
The four approved medications are used to treat Wilson’s disease, Gaucher’s disease, Tyrosinemia Type I and Dravet-Lennox Gastaut syndrome. Earlier, these therapies were imported to India and would cost Rs 18- 36 million (US$ 0.22- 0.44 million) for annual treatment of Gaucher’s disease alone. With this approval, patients with rare diseases can now access the therapy at a significantly reduced cost of Rs 0.3- 0.6 million (US$ 0.0037- 0.0073 million), which is 100 times less than the imported medicines. Over the next few months, the Indian Ministry will also be releasing medications for additional rare illnesses, such as hyperammonaemia and phenylketonuria.
Jithendra Kancharla, Pharma Analyst, GlobalData comments, “Rare diseases, by definition, afflict a small number of individuals in a population. In the vast population of India, rare diseases are often overlooked, and a silent struggle persists surrounding the diagnosis and treatment of rare diseases. In 2021, the Government of India has put forward the National Policy for Rare Diseases (NPRD-2021) to work on the lapses in fighting rare diseases. As a part of it, eight centers of excellence for the diagnosis and treatment of rare diseases are established, along with additional testing centers and financial support for patients undergoing treatment. Despite these initiatives, rare diseases continue to be a pressing healthcare issue in India.”
According to GlobalData’s Pharmaceutical Intelligence Center, the number of 10-year diagnosed prevalent cases of Wilson’s disease in India is expected to increase at an annual growth rate (AGR) of 0.36 per cent from 53,988 in 2023 to 55,150 in 2030. India has the second highest diagnosed prevalent cases among the major markets*, only next to China.
Rare diseases pose significant challenges due to the scarcity of information, limited research, and insufficient awareness among healthcare professionals and the public. The government must step up to create awareness among people and educate healthcare professionals about the symptoms, diagnosis, and treatment. This can be achieved through efficient social media and digital campaigns. The recent launch of LivAlert to promote awareness about Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) by National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) is a good example of efficient campaigning to increase disease awareness.
Jithendra concludes, “Improving rare disease awareness in India is a multifaceted challenge that requires coordinated efforts from various stakeholders, including the government, healthcare professionals, patient advocacy groups, and the media. Notably, collaboration with research institutes, pharma companies, and global rare disease networks is necessary to learn from international experiences.
“Big Pharma companies, by virtue of their resources and influence, have a significant role to play in promoting rare disease awareness. Additionally, focus on enhancing diagnostic facilities, especially in rural and underserved areas, to enable the early detection of rare diseases.”
*Major markets include Australia, Canada, China, France, Germany, India, Italy, Japan, South Korea, Spain, the UK, and the US.
- Advertisement -